Tricuspid atresia: Where are we now?

J Card Surg. 2020 Jul;35(7):1609-1617. doi: 10.1111/jocs.14673. Epub 2020 Jun 2.

Abstract

Tricuspid atresia (TA) is a complex congenital heart disease that presents with cyanosis in the neonatal period. It is invariably fatal if left untreated and requires multiple stages of palliation. Early recognition and timely surgical intervention are therefore pivotal in the management of these infants. This literature review considers the pathophysiology, presentation, investigations, and classification of TA. Moreover, it discusses the evidence upon which the latest medical and surgical treatments are based, as well as numerous recent case reports. Further work is needed to elucidate the etiology of TA, clarify the role of pharmacotherapy, and optimize the surgical management that these patients receive.

Keywords: congenital heart disease; management; palliation; tricuspid atresia.

Publication types

  • Review

MeSH terms

  • Alprostadil / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Child, Preschool
  • Female
  • Fontan Procedure / methods*
  • Fontan Procedure / mortality
  • Humans
  • Infant
  • Infant, Newborn
  • Male
  • Postoperative Care
  • Survival Rate
  • Treatment Outcome
  • Tricuspid Atresia / classification
  • Tricuspid Atresia / diagnosis
  • Tricuspid Atresia / mortality
  • Tricuspid Atresia / surgery*
  • Tricuspid Valve / surgery*

Substances

  • Angiotensin-Converting Enzyme Inhibitors
  • Alprostadil